Special Issue

Optical Genome Mapping in Hematological Malignancies

Message from the Guest Editors

For more than 40 years, the clinical evaluation of structural variation in hematological malignancies has primarily been driven by karyotyping. Karyotyping is a robust tool for evaluating structural and numerical changes in leukemia and other malignancies due to its ability to visualize and catalogue recurrent changes to chromosomes. As a result, many types of leukemia and lymphoma have a cytogenetic (i.e., karyotyping-based) classification system for diagnosis and prognosis. However, karyotyping suffers from several challenges, including the need for dividing cells (metaphases) and the relatively "low resolution" of the technique. Thus, ancillary testing, such as FISH or RT-PCR, is required to identify specific rearrangements between genes. Optical Genome Mapping is a new technology that can detect structural variation within a sample at a much higher resolution than karyotyping. As such, it is a promising new technique for the clinical evaluation of chromosomal changes in hematologic malignancies. The aim of this Special Issue is stimulate discussion around the use and adoption of Optical Genome Mapping for clinical diagnostics in hematological malignancies.

Guest Editors

Dr. Adam C. Smith

Dr. Alex Hoischen

Dr. Gordana Raca

Deadline for manuscript submissions

closed (31 August 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/100949

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

